Bifogade filer
Kurs & Likviditet
Beskrivning
Land | Danmark |
---|---|
Lista | First North Stockholm |
Sektor | Hälsovård |
Industri | Bioteknik |
Hørsholm, Denmark, September 22, 2022 - ExpreS2ion Biotech Holding AB's affiliate ExpreS2ion Biotechnologies ApS ("ExpreS2ion") announces that Pareto Securities has published a new research report on ExpreS2ion in September in which a new analyst, Marietta Miemietz, assumes coverage of the Company.
"The pipeline is progressing at a rapid pace. Bavarian Nordic commenced recruitment into the phase III trial for the COVID-19 vaccine ABNCoV2 earlier this month and aims for launches in the EU & US in 2023. In mid-2023, the company expects to finish pre-clinical work on the HER2-targeted breast cancer vaccine, potentially paving the way to first-in-human testing in 2024. We reiterate our Buy recommendation and set a price target of SEK 25/share." - Pareto Securities
The report provides an assessment of ExpreS[2]ion's pipeline, including potential near-term news flow, sum-of-the-parts analysis for estimating fair value per share and prospective financial estimates. Pareto sets a price target of SEK 25 per share based on the sum-of-the-parts valuation analysis, with upside to SEK 48 per share should COVID-19 become endemic in key Western markets.
The research report is available on the Analyst Reports (https://investor.expres2ionbio.com/analyst-reports/) page of ExpreS[2]ion's investor website.
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
Telefon: +46 11 32 30 732
E-post: ca@skmg.se